Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Alnylam Pharmaceuticals (ALNY)

NASDAQ: ALNY · Biotechnology · Cambridge, MA

Our rating: Positive

Positive reaffirmed at $165.00, moderate conviction, October 30, 2026.

Breaks if: Revenue growth falls below 20% year-over-year in any of the next four quarterly reports — against the current 65.2% — indicating the commercial ramp has plateaued well ahead of schedule and the operating-leverage thesis rests on a slower platform than the valuation implies; or free cash flow margin drops below 10% for two consecutive quarters, compared with today's implied 12.6% ($465M on $3.7B), signaling the cost base is expanding faster than the revenue engine. Either condition would shift the view toward Cautious.

Key figures

Market value$19.3B
Revenue, last 12 monthsn/a
Net income, last 12 months$2.6B
Free cash flow, last 12 monthsn/a
Price to earnings7.3×
Free cash flow yieldn/a
Dividend yield0.0%
Operating marginn/a
Return on equity126.6%
Beta to the S&P 5000.76
Volatility, annualized52.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.5B16.7%$15.72$271M
June 30, 2026$1.3B66.9%$1.21n/a
March 31, 2026n/an/an/an/a
December 31, 2025$1.1B84.9%$0.82$194M
September 30, 2025$1.2B149.3%$2.14$285M
June 30, 2025$774M17.3%$-0.55$114M
March 31, 2025$594M20.2%$-0.14−$127M
December 31, 2024$593M34.9%$-0.65−$104M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

17 ledger entries and 57 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.